Stay updated on SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma
Sign up to get notified when there's something new on the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page.

Latest updates to the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical-trial page displays the study record for SL-701 in recurrent glioblastoma, including its design, eligibility criteria, treatment arms, outcomes, and linked documents.SummaryDifference69%

- Check16 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide NIH notice announces a website transition and says agencies are using “Super Intelligence” instead of “Artificial Intelligence.” It appears above the inaccessible study record.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision identifier advanced from v3.7.1 to v3.7.2, while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0 on the 403 page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now displays a 403 Forbidden error view instead of the study content, indicating the record is inaccessible. The page shows the 403 banner along with a Home link and site footer, signaling that the record cannot be accessed at this time.SummaryDifference21%

Stay in the know with updates to SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma
Enter your email address, and we'll notify you when there's something new on the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page.